Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bombardieri

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 3, 2004
FDG-PET: procedure guidelines for tumour imagingEmilio Bombardieri, Cumali Aktolun, Richard P Baum, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2008
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshopPier Luigi Zinzani, Francesco d'Amore, Emilio Bombardieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantationLiliana Devizzi, Anna Guidetti, Corrado Tarella, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2010
111In-pentetreotide scintigraphy: procedure guidelines for tumour imagingEmilio Bombardieri, Valentina Ambrosini, Cumali Aktolun, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2012
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignanciesPaola A Erba, Martina Sollini, Enrico Orciuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survivalNatale Cascinelli, Emilio Bombardieri, Rosaria Bufalino, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary resultsCarlo Chiesa, Francesca Botta, Erika Di Betta, et al.
European Journal of Radiology|March 4, 2021
Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcomeEnzo Angeli, Serena Dalto, Stefano Marchese, et al.
Plos One|July 2, 2021
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infectionSerena Marchi, Simonetta Viviani, Edmond J Remarque, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 19, 2007
Sentinel node in breast cancer procedural guidelinesJohn Buscombe, Giovanni Paganelli, Zeynep E Burak, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Nuclear Medicine and Molecular Imaging|March 3, 2004
FDG-PET: procedure guidelines for tumour imagingEmilio Bombardieri, Cumali Aktolun, Richard P Baum, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2008
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshopPier Luigi Zinzani, Francesco d'Amore, Emilio Bombardieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantationLiliana Devizzi, Anna Guidetti, Corrado Tarella, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2010
111In-pentetreotide scintigraphy: procedure guidelines for tumour imagingEmilio Bombardieri, Valentina Ambrosini, Cumali Aktolun, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2012
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignanciesPaola A Erba, Martina Sollini, Enrico Orciuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survivalNatale Cascinelli, Emilio Bombardieri, Rosaria Bufalino, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary resultsCarlo Chiesa, Francesca Botta, Erika Di Betta, et al.
European Journal of Radiology|March 4, 2021
Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcomeEnzo Angeli, Serena Dalto, Stefano Marchese, et al.
Plos One|July 2, 2021
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infectionSerena Marchi, Simonetta Viviani, Edmond J Remarque, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 19, 2007
Sentinel node in breast cancer procedural guidelinesJohn Buscombe, Giovanni Paganelli, Zeynep E Burak, et al.
Pageof 9